enVVeno Medical Corporation
NVNO Healthcare Medical Devices
In the quarter to June 2026, EPS grew 53.6% and free cash flow grew 4.60%, each against the same quarter a year earlier.
Follow NVNO
enVVeno Medical Corporation (NVNO) EV/Sales
As of 16 October 2026, enVVeno Medical Corporation (NVNO) trades at a EV/Sales of −63.5×. Over the past ten years it has ranged from −108× (December 2025) to 408× (July 2025); the current reading is higher than 9% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 63.7× | (23.82%) |
| FY2018 | 83.6× | (33.28%) |
| FY2017 | 125× | 0.00% |
| FY2016 | 125× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2019 | 120× | 43.20% |
| Dec 2018 | 83.6× | (15.23%) |
| Sep 2018 | 98.7× | 22.65% |
| Jun 2018 | 80.5× | (35.83%) |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVNO enVVeno Medical Corporation | −63.5× |
| CODX Co-Diagnostics, Inc. compare | −1.2× |
| AMIX Autonomix Medical, Inc. compare | n/m |
| WOK WORK Medical Technology Group LTD compare | n/m |
| TBIO Telesis Bio Inc. compare | 0.1× |
| INBS Intelligent Bio Solutions Inc. compare | 0.2× |
| VVOS Vivos Therapeutics, Inc. compare | 0.4× |
| TRIB Trinity Biotech PLC compare | 3.0× |
| VNRX VolitionRX Limited compare | 4.0× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)